Chief Financial Officer · MoonLake Immunotherapeutics (MLTX)

Matthias Bodenstedt

A named executive officer of MoonLake Immunotherapeutics in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$4,692,576

FY2024: $1,032,555

Compensation figures as of the proxy filed April 21, 2026 (DEF 14A).

Matthias Bodenstedt compensation by year

MoonLake Immunotherapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as MoonLake Immunotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$446,837$552,777$603,555
Bonus$424,491$413,289$0
Stock awards$0$0$4,000,021
Option awards$0$0$0
Non-equity incentive$0$0$0
Pension and deferred compensation$0$44,687$66,023
All other$20,269$21,802$22,977
Total$891,597$1,032,555$4,692,576

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MoonLake Immunotherapeutics DEF 14A filed April 21, 2026, accession 0001140361-26-015916, and prior-year filings. Open the filing on EDGAR.

$892K
$1.0M
$4.7M
FY23
FY24
FY25
SalaryBonusStock awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU95,763$1,262,156—
RSU11,101$146,311—

Per the Outstanding Equity Awards at Fiscal Year-End table in MoonLake Immunotherapeutics's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments MoonLake Immunotherapeutics discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Change in control, no termination$0$1,408,467$0$1,408,467
Voluntary resignation$0$0$0$0
Change in control and involuntary termination$0$1,408,467$0$1,408,467
Involuntary termination without cause$0$0$0$0

Per the Potential Payments Upon Termination or Change in Control table in MoonLake Immunotherapeutics's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

MoonLake Immunotherapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Jorge Santos da SilvaChief Executive Officer; Interim Chair of the Board$4,943,209
Kristian ReichChief Scientific Officer$4,795,493
Matthias Bodenstedt · this pageChief Financial Officer$4,692,576

The full MoonLake Immunotherapeutics compensation record

free company brief

This page is one person within MoonLake Immunotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MoonLake Immunotherapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MoonLake Immunotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy